Progress on predictive methods for loss of response to infliximab treatment in pediatric Crohn's disease
Infliximab is one of the most extensively used biological agents in the treatment of Crohn's disease,but in the actual application process,some patients may have loss of response,which may lead to the refactory disease and the rise of treatment cost.Identifying loss of response at an early phase has become a crucial component of treatment,but the academic community has not a unified prediction standard yet.This article reviews the recent indicators for predicting loss of response to infliximab treatment,such as infliximab concentration and anti-antibody monitoring,serological indicators,ultrasound,magnetic resonance imaging and endoscopy,clinical indicators of Crohn's disease,HLA-DQA1*05 gene,newly developed models and indicators and their criteria.
InfliximabCrohn's diseaseLoss of responsePrediction
NETL
NSTL
万方数据
